Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment of multiple sclerosis with the pregnancy hormone estriol.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
45th European Brain and Behaviour Society Meeting
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Extension CombiRx data show no benefit of combined MS drugs
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Pages